Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,766.40
(
0.19%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.07
(
0.61%
)
Bitcoin
71,151.00
(
1.79%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: DewDiligence post# 31323

Saturday, 07/15/2006 5:02:33 PM

Saturday, July 15, 2006 5:02:33 PM

Post# of 257262
Piper says it has learned that BMY has discontinued development of its early stage HCV protease inhibitor while saying it is no longer pursuing drug candidates in HCV. The development is seen as a clear positive for VRTX as investors believed the compound could have been a potentially serious competitor to VX-950.

From the fabulous folks at StreetAccount.com 7:38am Friday morning.

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now